{"id":"nx","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":{"setId":"7e67e73e-ddf4-4e4d-8b50-09d7514910b6","title":"ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [DAIICHI SANKYO INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Nexium, a proton pump inhibitor, blocks the enzyme system in the stomach lining responsible for acid production. This leads to a decrease in gastric acid secretion, which helps to alleviate symptoms of acid reflux and other conditions.","oneSentence":"Nexium works by reducing the amount of acid produced in the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:44.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Erosive esophagitis"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT05627063","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-06-26","conditions":"Solid Tumor","enrollment":169},{"nctId":"NCT06270953","phase":"","title":"Non-invasive Monitoring: Impact on Patient Management and Outcomes","status":"COMPLETED","sponsor":"Turtle Shell Technologies Pvt. Ltd.","startDate":"2024-01-19","conditions":"No Specific Medical Conditions or Disease States","enrollment":54},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT05893888","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Privo Technologies","startDate":"2024-11-07","conditions":"Oral Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT07020026","phase":"PHASE2","title":"Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease","status":"RECRUITING","sponsor":"Michael J. Fox Foundation for Parkinson's Research","startDate":"2025-05-12","conditions":"Parkinson's Disease","enrollment":60},{"nctId":"NCT04802629","phase":"","title":"Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2020-06-08","conditions":"Preterm Birth, Oxygen Toxicity, Fetal Hemoglobin","enrollment":50},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT03025958","phase":"PHASE2","title":"Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2017-03-13","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT05107739","phase":"PHASE1","title":"A Study of DeTIL-0255 in Adults With Advanced Malignancies","status":"TERMINATED","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-12-22","conditions":"Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer","enrollment":5},{"nctId":"NCT06283576","phase":"","title":"Pancreatic Cancer Initial Detection Via Liquid Biopsy","status":"ENROLLING_BY_INVITATION","sponsor":"Karolinska University Hospital","startDate":"2024-05-01","conditions":"Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk","enrollment":200},{"nctId":"NCT02086045","phase":"NA","title":"Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial","status":"COMPLETED","sponsor":"Elixir Medical Corporation","startDate":"2011-11","conditions":"Coronary Artery Disease","enrollment":126},{"nctId":"NCT05863728","phase":"NA","title":"Post-Operative Evaluation of Endodontic Microsurgeries Done Using a Piezoelectric Ultrasonic Technique: An in Vivo Study","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2020-01-01","conditions":"Periapical Diseases, Endodontic Overfill, Healing Surgical Wounds","enrollment":20},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT05548101","phase":"NA","title":"Prospective, Randomized Trial Comparing ICSI to Insemination for Non-Male Factor Patients Undergoing PGT-A","status":"UNKNOWN","sponsor":"Texas Fertility Center","startDate":"2022-11-01","conditions":"Infertility","enrollment":500},{"nctId":"NCT00270257","phase":"PHASE3","title":"Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Opioid-Related Disorders","enrollment":1251},{"nctId":"NCT00544765","phase":"PHASE3","title":"Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-09","conditions":"Breast Cancer","enrollment":2014},{"nctId":"NCT02672111","phase":"PHASE3","title":"Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-11","conditions":"Opioid Use Disorder","enrollment":228},{"nctId":"NCT00006036","phase":"PHASE1","title":"Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-03-22","conditions":"Head and Neck Cancer, Lung Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT00010179","phase":"PHASE2","title":"Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-10-31","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":81},{"nctId":"NCT04307147","phase":"PHASE3","title":"NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-07-03","conditions":"Breast Cancer","enrollment":316},{"nctId":"NCT00541112","phase":"PHASE2","title":"Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2007-10-29","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT01671319","phase":"PHASE2","title":"Dose Dense TC + Pegfilgrastim Support for Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2011-06","conditions":"Female Breast Cancer","enrollment":42},{"nctId":"NCT02651584","phase":"PHASE3","title":"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-12","conditions":"Opioid Use Disorders","enrollment":428},{"nctId":"NCT01967641","phase":"PHASE2","title":"Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-11","conditions":"Opioid Dependence","enrollment":51},{"nctId":"NCT00431184","phase":"PHASE2","title":"Effects of Pentazocine Versus Lorazepam on Manic Symptoms","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2007-01","conditions":"Bipolar Disorder, Schizoaffective Disorder, Manic Disorder","enrollment":19},{"nctId":"NCT03052504","phase":"","title":"Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy","status":"COMPLETED","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2016-09","conditions":"Bladder Cancer, Renal Cell Carcinoma","enrollment":156},{"nctId":"NCT03359694","phase":"PHASE3","title":"Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12","conditions":"Susceptibility, Genetic, Chemotherapy Effect","enrollment":300},{"nctId":"NCT02489409","phase":"PHASE2","title":"Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2015-10","conditions":"Breast Neoplasms","enrollment":120},{"nctId":"NCT02516436","phase":"PHASE3","title":"The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects","status":"WITHDRAWN","sponsor":"BioDelivery Sciences International","startDate":"","conditions":"Opioid Dependence","enrollment":""},{"nctId":"NCT01713803","phase":"PHASE3","title":"Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects","status":"WITHDRAWN","sponsor":"BioDelivery Sciences International","startDate":"","conditions":"Opioid Dependence","enrollment":""},{"nctId":"NCT01666119","phase":"PHASE2","title":"An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2012-08","conditions":"Opioid Dependence","enrollment":249},{"nctId":"NCT00000353","phase":"PHASE2","title":"Trial of Buprenorphine/Naloxone for Opiate Dependence - 2","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-10","conditions":"Opioid-Related Disorders, Substance-Related Disorders","enrollment":""},{"nctId":"NCT00015171","phase":"PHASE3","title":"Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-04","conditions":"Heroin Dependence, Substance-Related Disorders","enrollment":""},{"nctId":"NCT01359930","phase":"PHASE1","title":"Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2011-08","conditions":"Methamphetamine Dependence","enrollment":16},{"nctId":"NCT00015340","phase":"PHASE4","title":"Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1999-08","conditions":"Opioid Dependence, Substance-Related Disorders","enrollment":582},{"nctId":"NCT00078130","phase":"PHASE3","title":"Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2003-07","conditions":"Opioid-Related Disorders","enrollment":223},{"nctId":"NCT00315341","phase":"PHASE4","title":"Starting Treatment With Agonist Replacement Therapies (START)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-04","conditions":"Opiate-related Disorders","enrollment":1269},{"nctId":"NCT00817739","phase":"PHASE2","title":"Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c","status":"COMPLETED","sponsor":"Takeda","startDate":"1996-12","conditions":"Prostatic Neoplasms","enrollment":341},{"nctId":"NCT00125931","phase":"PHASE2","title":"Effects of Pentazocine on Manic Symptoms","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":10},{"nctId":"NCT00297141","phase":"PHASE2","title":"Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2004-10","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT00316277","phase":"PHASE3","title":"Prescription Opioid Addiction Treatment Study (POATS)","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2006-05","conditions":"Opiate Dependence, Substance-related Disorders, Opioid-related Disorders","enrollment":653},{"nctId":"NCT00014586","phase":"PHASE3","title":"Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-01","conditions":"Prostate Cancer","enrollment":110},{"nctId":"NCT00022594","phase":"PHASE2","title":"Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-05","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT01478230","phase":"EARLY_PHASE1","title":"An Exploratory Study Comparing Two Nicotine Inhalers","status":"COMPLETED","sponsor":"McNeil AB","startDate":"2011-11","conditions":"Tobacco Dependence","enrollment":36},{"nctId":"NCT00003640","phase":"PHASE2","title":"Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-09","conditions":"Bladder Cancer","enrollment":73},{"nctId":"NCT01126138","phase":"PHASE3","title":"Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2010-07","conditions":"Carcinoma, Invasive Ductal, Breast","enrollment":200},{"nctId":"NCT00361855","phase":"PHASE1","title":"Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle","status":"COMPLETED","sponsor":"Neuronyx","startDate":"2006-04","conditions":"Myocardial Infarction","enrollment":18},{"nctId":"NCT00490880","phase":"PHASE2","title":"Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-11","conditions":"Bladder Cancer","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"CONFUSIONAL STATE"},{"count":14,"reaction":"NAUSEA"},{"count":13,"reaction":"ANXIETY"},{"count":13,"reaction":"DEPRESSION"},{"count":12,"reaction":"ABNORMAL DREAMS"},{"count":12,"reaction":"HALLUCINATION"},{"count":11,"reaction":"AMNESIA"},{"count":11,"reaction":"DRUG HYPERSENSITIVITY"},{"count":11,"reaction":"NERVOUSNESS"},{"count":10,"reaction":"VISUAL DISTURBANCE"}],"_approvalHistory":[],"publicationCount":3051,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Navelbine and Xeloda"],"phase":"marketed","status":"active","brandName":"NX","genericName":"NX","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nexium works by reducing the amount of acid produced in the stomach. Used for Erosive esophagitis, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}